Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.

Yu H, Truong H, Mitchell SA, Liclican A, Gosink JJ, Li W, Lin J, Feng JY, Jürgensmeier JM, Billin A, Xu R, Patterson S, Pagratis N.

SLAS Discov. 2018 Jul 1:2472555218786165. doi: 10.1177/2472555218786165. [Epub ahead of print]

PMID:
30011241
2.

A Novel Small-Molecule Inhibitor Targeting CREB-CBP Complex Possesses Anti-Cancer Effects along with Cell Cycle Regulation, Autophagy Suppression and Endoplasmic Reticulum Stress.

Lee JW, Park HS, Park SA, Ryu SH, Meng W, Jürgensmeier JM, Kurie JM, Hong WK, Boyer JL, Herbst RS, Koo JS.

PLoS One. 2015 Apr 21;10(4):e0122628. doi: 10.1371/journal.pone.0122628. eCollection 2015.

3.

New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.

Jürgensmeier JM, Eder JP, Herbst RS.

Clin Cancer Res. 2014 Sep 1;20(17):4425-35. doi: 10.1158/1078-0432.CCR-13-0753.

4.

Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.

Pommier AJ, Shaw R, Spencer SK, Morgan SR, Hoff PM, Robertson JD, Barry ST, Jürgensmeier JM.

Br J Cancer. 2014 Oct 14;111(8):1590-604. doi: 10.1038/bjc.2014.436. Epub 2014 Aug 14.

5.

Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.

Judson I, Scurr M, Gardner K, Barquin E, Marotti M, Collins B, Young H, Jürgensmeier JM, Leahy M.

Clin Cancer Res. 2014 Jul 1;20(13):3603-12. doi: 10.1158/1078-0432.CCR-13-1881. Epub 2014 Apr 8.

6.

Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms.

Decio A, Taraboletti G, Patton V, Alzani R, Perego P, Fruscio R, Jürgensmeier JM, Giavazzi R, Belotti D.

Am J Pathol. 2014 Apr;184(4):1050-1061. doi: 10.1016/j.ajpath.2013.12.030. Epub 2014 Feb 6. Erratum in: Am J Pathol. 2014 Jul;184(7):2144.

PMID:
24508126
7.

Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.

Bar J, Spencer S, Morgan S, Brooks L, Cunningham D, Robertson J, Jürgensmeier JM, Goss GD.

Clin Colorectal Cancer. 2014 Mar;13(1):46-53. doi: 10.1016/j.clcc.2013.11.002. Epub 2013 Nov 13.

PMID:
24355210
8.

Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.

Spencer SK, Pommier AJ, Morgan SR, Barry ST, Robertson JD, Hoff PM, Jürgensmeier JM.

Br J Cancer. 2013 Nov 26;109(11):2765-73. doi: 10.1038/bjc.2013.649. Epub 2013 Oct 22.

9.

Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.

Burford A, Little SE, Jury A, Popov S, Laxton R, Doey L, Al-Sarraj S, Jürgensmeier JM, Jones C.

PLoS One. 2013 Aug 21;8(8):e71777. doi: 10.1371/journal.pone.0071777. eCollection 2013.

10.

Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.

Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, Degroot J, Gattamaneni R, Cher L, Rosenthal M, Payer F, Jürgensmeier JM, Jain RK, Sorensen AG, Xu J, Liu Q, van den Bent M.

J Clin Oncol. 2013 Sep 10;31(26):3212-8. doi: 10.1200/JCO.2012.47.2464. Epub 2013 Aug 12.

11.

KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.

Smith JC, Brooks L, Hoff PM, McWalter G, Dearden S, Morgan SR, Wilson D, Robertson JD, Jürgensmeier JM.

Eur J Cancer. 2013 Jul;49(10):2424-32. doi: 10.1016/j.ejca.2013.02.023. Epub 2013 Mar 16.

PMID:
23510802
12.

IDH1-associated primary glioblastoma in young adults displays differential patterns of tumour and vascular morphology.

Popov S, Jury A, Laxton R, Doey L, Kandasamy N, Al-Sarraj S, Jürgensmeier JM, Jones C.

PLoS One. 2013;8(2):e56328. doi: 10.1371/journal.pone.0056328. Epub 2013 Feb 22.

13.

Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.

Jürgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, Wilson D, Hoff PM.

Br J Cancer. 2013 Apr 2;108(6):1316-23. doi: 10.1038/bjc.2013.79. Epub 2013 Feb 28.

14.

Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.

Kendrew J, Odedra R, Logié A, Taylor PJ, Pearsall S, Ogilvie DJ, Wedge SR, Jürgensmeier JM.

Cancer Chemother Pharmacol. 2013 Apr;71(4):1021-32. doi: 10.1007/s00280-013-2097-x. Epub 2013 Jan 26.

PMID:
23355042
15.

Receptor tyrosine kinase genes amplified in glioblastoma exhibit a mutual exclusivity in variable proportions reflective of individual tumor heterogeneity.

Little SE, Popov S, Jury A, Bax DA, Doey L, Al-Sarraj S, Jurgensmeier JM, Jones C.

Cancer Res. 2012 Apr 1;72(7):1614-20. doi: 10.1158/0008-5472.CAN-11-4069. Epub 2012 Feb 6.

16.

Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.

Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, Protheroe A, van Herpen CM, Mookerjee B, Pike L, Jürgensmeier JM, Gore ME.

Eur J Cancer. 2012 Mar;48(4):527-37. doi: 10.1016/j.ejca.2011.12.022. Epub 2012 Jan 28.

PMID:
22285180
17.

Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.

Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS.

Clin Cancer Res. 2012 Mar 15;18(6):1641-54. doi: 10.1158/1078-0432.CCR-11-2324. Epub 2012 Jan 24.

18.

Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.

Brave SR, Ratcliffe K, Wilson Z, James NH, Ashton S, Wainwright A, Kendrew J, Dudley P, Broadbent N, Sproat G, Taylor S, Barnes C, Silva JC, Farnsworth CL, Hennequin L, Ogilvie DJ, Jürgensmeier JM, Shibuya M, Wedge SR, Barry ST.

Mol Cancer Ther. 2011 May;10(5):861-73. doi: 10.1158/1535-7163.MCT-10-0976. Epub 2011 Mar 25.

19.

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

Smith NR, Baker D, James NH, Ratcliffe K, Jenkins M, Ashton SE, Sproat G, Swann R, Gray N, Ryan A, Jürgensmeier JM, Womack C.

Clin Cancer Res. 2010 Jul 15;16(14):3548-61. doi: 10.1158/1078-0432.CCR-09-2797. Epub 2010 Jul 6.

20.

Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.

van Cruijsen H, Voest EE, Punt CJ, Hoekman K, Witteveen PO, Meijerink MR, Puchalski TA, Robertson J, Saunders O, Jürgensmeier JM, van Herpen CM, Giaccone G.

Eur J Cancer. 2010 Mar;46(5):901-11. doi: 10.1016/j.ejca.2009.12.023. Epub 2010 Jan 12.

PMID:
20061136
21.

Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma.

Medinger M, Esser N, Zirrgiebel U, Ryan A, Jürgensmeier JM, Drevs J.

Anticancer Res. 2009 Dec;29(12):5065-76.

22.

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines.

Morelli MP, Brown AM, Pitts TM, Tentler JJ, Ciardiello F, Ryan A, Jürgensmeier JM, Eckhardt SG.

Mol Cancer Ther. 2009 Sep;8(9):2546-58. doi: 10.1158/1535-7163.MCT-09-0380. Epub 2009 Sep 15.

23.

An open-label, Phase I study of cediranib (RECENTIN) in patients with acute myeloid leukemia.

Fiedler W, Mesters R, Heuser M, Ehninger G, Berdel WE, Zirrgiebel U, Robertson JD, Puchalski TA, Collins B, Jürgensmeier JM, Serve H.

Leuk Res. 2010 Feb;34(2):196-202. doi: 10.1016/j.leukres.2009.07.020. Epub 2009 Aug 11.

PMID:
19674789
24.

The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.

Siemann DW, Brazelle WD, Jürgensmeier JM.

Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):897-903. doi: 10.1016/j.ijrobp.2008.10.031.

25.

Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate.

Bradley DP, Tessier JJ, Lacey T, Scott M, Jürgensmeier JM, Odedra R, Mills J, Kilburn L, Wedge SR.

Magn Reson Imaging. 2009 Apr;27(3):377-84. doi: 10.1016/j.mri.2008.07.021. Epub 2008 Sep 23.

PMID:
18814988
26.

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.

Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, Wedge SR, Jürgensmeier JM, Alitalo K.

Cancer Res. 2008 Jun 15;68(12):4754-62. doi: 10.1158/0008-5472.CAN-07-5809.

27.

Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.

Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jürgensmeier JM, Milas L, Ang K, Herbst RS, O'Reilly MS.

Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1534-43. Epub 2007 Sep 24.

28.

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.

Smith NR, James NH, Oakley I, Wainwright A, Copley C, Kendrew J, Womersley LM, Jürgensmeier JM, Wedge SR, Barry ST.

Mol Cancer Ther. 2007 Aug;6(8):2198-208.

29.

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.

Drevs J, Siegert P, Medinger M, Mross K, Strecker R, Zirrgiebel U, Harder J, Blum H, Robertson J, Jürgensmeier JM, Puchalski TA, Young H, Saunders O, Unger C.

J Clin Oncol. 2007 Jul 20;25(21):3045-54.

PMID:
17634482
30.

Lysosomal membrane permeabilization during apoptosis--involvement of Bax?

Kågedal K, Johansson AC, Johansson U, Heimlich G, Roberg K, Wang NS, Jürgensmeier JM, Ollinger K.

Int J Exp Pathol. 2005 Oct;86(5):309-21.

31.

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.

Wedge SR, Kendrew J, Hennequin LF, Valentine PJ, Barry ST, Brave SR, Smith NR, James NH, Dukes M, Curwen JO, Chester R, Jackson JA, Boffey SJ, Kilburn LL, Barnett S, Richmond GH, Wadsworth PF, Walker M, Bigley AL, Taylor ST, Cooper L, Beck S, Jürgensmeier JM, Ogilvie DJ.

Cancer Res. 2005 May 15;65(10):4389-400.

32.

c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers.

Peltenburg LT, de Bruin EC, Meersma D, Wilting S, Jürgensmeier JM, Schrier PI.

Melanoma Res. 2004 Feb;14(1):3-12.

PMID:
15091188
33.

Bax-induced cytochrome c release from mitochondria depends on alpha-helices-5 and -6.

Heimlich G, McKinnon AD, Bernardo K, Brdiczka D, Reed JC, Kain R, Krönke M, Jürgensmeier JM.

Biochem J. 2004 Feb 15;378(Pt 1):247-55.

34.

XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells.

Kashkar H, Haefs C, Shin H, Hamilton-Dutoit SJ, Salvesen GS, Kronke M, Jurgensmeier JM.

J Exp Med. 2003 Jul 21;198(2):341-7.

35.

Defective Bax activation in Hodgkin B-cell lines confers resistance to staurosporine-induced apoptosis.

Kashkar H, Krönke M, Jürgensmeier JM.

Cell Death Differ. 2002 Jul;9(7):750-7.

36.

Methods of assaying Bcl-2 and Bax family proteins in yeast.

Xu Q, Jürgensmeier JM, Reed JC.

Methods. 1999 Apr;17(4):292-304.

PMID:
10196100
37.

Pro-caspase-3 is a major physiologic target of caspase-8.

Stennicke HR, Jürgensmeier JM, Shin H, Deveraux Q, Wolf BB, Yang X, Zhou Q, Ellerby HM, Ellerby LM, Bredesen D, Green DR, Reed JC, Froelich CJ, Salvesen GS.

J Biol Chem. 1998 Oct 16;273(42):27084-90.

38.

Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis.

Marzo I, Brenner C, Zamzami N, Jürgensmeier JM, Susin SA, Vieira HL, Prévost MC, Xie Z, Matsuyama S, Reed JC, Kroemer G.

Science. 1998 Sep 25;281(5385):2027-31.

39.

Bcl-2 family proteins and mitochondria.

Reed JC, Jurgensmeier JM, Matsuyama S.

Biochim Biophys Acta. 1998 Aug 10;1366(1-2):127-37.

40.

Bax directly induces release of cytochrome c from isolated mitochondria.

Jürgensmeier JM, Xie Z, Deveraux Q, Ellerby L, Bredesen D, Reed JC.

Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4997-5002.

41.

Interference of bcl-2 with intercellular control of carcinogenesis.

Jürgensmeier JM, Bauer G.

Int J Cancer. 1997 May 16;71(4):698-704.

42.

Reactive oxygen species as mediators of the transformed phenotype.

Jürgensmeier JM, Panse J, Schäfer R, Bauer G.

Int J Cancer. 1997 Mar 4;70(5):587-9.

43.

Bax- and Bak-induced cell death in the fission yeast Schizosaccharomyces pombe.

Jürgensmeier JM, Krajewski S, Armstrong RC, Wilson GM, Oltersdorf T, Fritz LC, Reed JC, Ottilie S.

Mol Biol Cell. 1997 Feb;8(2):325-39.

44.
46.

Transforming growth factor beta-treated normal fibroblasts eliminate transformed fibroblasts by induction of apoptosis.

Jürgensmeier JM, Schmitt CP, Viesel E, Höfler P, Bauer G.

Cancer Res. 1994 Jan 15;54(2):393-8.

Supplemental Content

Loading ...
Support Center